Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.52
-0.46 (-3.51%)
At close: Apr 28, 2026, 4:00 PM EDT
12.54
+0.02 (0.20%)
After-hours: Apr 28, 2026, 4:10 PM EDT

Contineum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--50--
Gross Profit
--50--
Selling, General & Admin
18.7713.667.266.636.29
Research & Development
49.2937.2426.6716.0922.36
Operating Expenses
68.0650.8933.9222.7228.65
Operating Income
-68.06-50.8916.08-22.72-28.65
Interest Expense
---0.21-0.39-0.33
Interest & Investment Income
8.258.914.610.760.08
Other Non Operating Income (Expenses)
-0.17-0.272.7-1.91-0.1
Pretax Income
-59.98-42.2623.17-24.25-29
Income Tax Expense
--0.45--
Net Income
-59.98-42.2622.72-24.25-29
Preferred Dividends & Other Adjustments
--19.57--
Net Income to Common
-59.98-42.263.15-24.25-29
Shares Outstanding (Basic)
2819222
Shares Outstanding (Diluted)
2819322
Shares Change (YoY)
43.14%469.95%51.38%6.35%-
EPS (Basic)
-2.17-2.181.36-10.81-13.75
EPS (Diluted)
-2.17-2.180.08-10.81-13.77
Free Cash Flow
-55.54-33.3618.94-20.24-26.43
Free Cash Flow Per Share
-2.00-1.725.58-9.02-12.53
Gross Margin
--100.00%--
Operating Margin
--32.15%--
Profit Margin
--6.29%--
Free Cash Flow Margin
--37.87%--
EBITDA
-67.74-50.6416.27-22.39-28.32
EBITDA Margin
--32.54%--
D&A For EBITDA
0.320.260.20.330.33
EBIT
-68.06-50.8916.08-22.72-28.65
EBIT Margin
--32.15%--
Effective Tax Rate
--1.94%--
Source: S&P Capital IQ. Standard template. Financial Sources.